Company Overview
| Stock Name | 3D Medicines |
|---|---|
| Stock Code | 01244 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家成立於2014年的生物醫藥公司,致力於為癌症患者,尤其是那些需要長期治療的患者研發腫瘤藥物。核心業務模式是通過聯合合作開發、許可引進及自主發現等方式,開發及商業化腫瘤產品及候選藥物。 |
| Listing Date | 2022-12-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國 上海市 浦東新區 芙蓉花路118號 11號樓 |
| Business Address (Hong Kong) | 香港 德輔道中188號 金龍中心14樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | 3d-medicines.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 24.98 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 0.001 / shares |
| Offer Period | 2022-11-29 to 2022-12-07 |
| Global Offering Shares | 16,350,000 shares |
| HK Public Offer Shares (Initial) | 1,635,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 14,715,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 255,642,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 57.4% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 408,423,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 821.8M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +1082% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 6,385,937,160 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2020 | 2021 |
|---|---|---|
| Revenue | 60,260 | 161,062 |
| Cost of sales | -4,277 | -11,458 |
| Gross profit | 55,983 | 149,604 |
| Other income and gains, net | 2,337 | 21,480 |
| Selling and distribution expenses | 0 | -103,567 |
| Administrative expenses | -40,528 | -46,631 |
| Net finance costs | -8,058 | -740 |
| Profit before tax | -635,380 | -1,461,825 |
| Income tax expense | 0 | 0 |
| Profit for the year | -635,380 | -1,461,825 |
| Profit attributable to owners | -635,380 | -1,434,092 |
Balance Sheet
| Item | 2020 | 2021 | 2022-05 |
|---|---|---|---|
| Cash and cash equivalents | 414,261 | 774,306 | |
| Trade and bills receivables | 0 | 65,004 | |
| Inventories | 0 | 13 | |
| Total current assets | 461,755 | 919,227 | |
| Total assets | 496,216 | 1,060,293 | |
| Total current liabilities | 315,008 | 3,248,045 | |
| Total liabilities | 1,766,031 | 3,332,855 | |
| Total equity | -1,269,815 | -2,272,562 | |
| Equity attributable to owners | -1,269,815 | -2,238,011 | |
| Interest-bearing borrowings | 3,522 | 0 | 0 |
Cash Flow Statement
| Item | 2020 | 2021 | 2022-05 |
|---|---|---|---|
| Net cash from operating activities | -278,329 | -377,079 | |
| Net cash from investing activities | -20,480 | -98,871 | |
| Depreciation of PP&E | 1,153 | 3,750 | 3,331 |
| Depreciation of right-of-use assets | 2,218 | 8,757 | 5,442 |
| Amortisation of intangible assets | 0 | 84 | 42 |
| Purchase of PP&E | -11,147 | -43,872 | -16,248 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 31.45 |
|---|---|
| First Day Open | HK$ 29.0 |
| First Day Change | 25.90% |
| First Day Volume | 1515300.0 |
| First Day Turnover | 44431600.0 |
| Use of Proceeds | 1、約55%,或138.1百萬港元,將用于公司的核心產品恩沃利單抗;
2、約25%,或62.8百萬港元,將用于公司的其他候選藥物;
3、約10%,或25.1百萬港元,將用于建造公司位于江蘇省徐州市的內部生產設施及采購新機器、儀器和設備;
4、約10%,或25.1百萬港元,將用于公司的一般企業及營運資金用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (3)
Joint Bookrunners (8)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
中信建投(国际)融资有限公司 CE BAU112
CNCB (Hong Kong) Capital Limited CE AEQ982
建银国际金融有限公司 CE AJO225
XinKong International Securities Limited CE ACV085
Livermore Holdings Limited CE BJN764
农银国际证券有限公司 CE ACX411
老虎证券(香港)环球有限公司 CE BMU940
Joint Lead Managers (13)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
中信建投(国际)融资有限公司 CE BAU112
CNCB (Hong Kong) Capital Limited CE AEQ982
建银国际金融有限公司 CE AJO225
XinKong International Securities Limited CE ACV085
Livermore Holdings Limited CE BJN764
农银国际证券有限公司 CE ACX411
老虎证券(香港)环球有限公司 CE BMU940
SDHG International Securities Limited CE ADY241
Lego Securities Limited CE BIE918
VALUABLE CAPITAL LIMITED CE AUL711
富途证券国际(香港)有限公司 CE AZT137
VICTORY SECURITIES COMPANY LIMITED CE ABN091
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 78,449,690 HKD | — | 19.21% | — | 6 months | 2023-06-15 |
| 2 | Mobilewise Limited | 31,374,880 HKD | — | 7.68% | — | 6 months | 2023-06-15 |
| 3 | 好赞资产管理有限公司 | 78,449,690 HKD | — | 19.21% | — | 6 months | 2023-06-15 |
| 4 | 徐州经济技术开发区(香港)投资有限公司 | 46,325,410 HKD | — | 11.34% | — | 6 months | 2023-06-15 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 龔兆龍 | — |
| Company Secretary | 夏芳、李菁怡 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 龔兆龍博士(透過Dragon Prosper及股份激勵平台)持有約31.06%股份(緊接全球發售前),先聲藥業集團持股約9.63%,深圳倚鋒持股約5.77%。 |
|---|




